Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
QuintilesIMS
Merck
Cantor Fitzgerald
Dow
Healthtrust
Farmers Insurance
Fuji
Fish and Richardson

Generated: June 19, 2018

DrugPatentWatch Database Preview

XYLO-PFAN Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Xylo-pfan patents expire, and what generic alternatives are available?

Xylo-pfan is a drug marketed by Savage Labs and is included in one NDA.

The generic ingredient in XYLO-PFAN is xylose. There is one drug master file entry for this compound. Additional details are available on the xylose profile page.
Summary for XYLO-PFAN
Drug patent expirations by year for XYLO-PFAN
Synonyms for XYLO-PFAN
(3R,4S,5R)-oxane-2,3,4,5-tetrol
(3R,4S,5R)-Tetrahydro-2H-pyran-2,3,4,5-tetraol
(3R,4S,5R)-tetrahydro-2H-pyran-2,3,4,5-tetrol
058X866
10257-31-5
50855-32-8
7261-26-9
AC-11300
AC1L35YW
AK432529
AKOS025401342
AS-11757
BDBM16234
BT000158
C00181
CA000116
CAS-58-86-6
CHEBI:53455
CHEMBL502135
cid_135191
CTK0H1735
D -Xylose
D-(+)-Xylose, >=99%
D-(+)-Xylose, 99%, natural sourced
D-(+)-Xylose, analytical standard
D-(+)-Xylose, BioUltra, >=99.0% (sum of enantiomers, HPLC)
D-(+)-Xylose, BioXtra, >=99%
D-(+)-Xylose, puriss., 98.5%
D-(+)-Xylose, SAJ special grade, 98.0-101.0%
D-Xyl
D-xylopentose
D-Xylopyranose
D-Xylopyranose (9CI)
D-Xylopyranoside
D-Xylose
D06346
D07HZY
DSSTox_CID_3745
DSSTox_GSID_23745
DSSTox_RID_77180
DTXSID0023745
Epitope ID:114701
F8887-9207
MFCD00064360
MLS001361339
MolPort-003-934-029
NCGC00165998-01
NCGC00255319-01
NE11127
SCHEMBL39891
SMR000857378
SRBFZHDQGSBBOR-IOVATXLUSA-N
Tox21_302055
Wood sugar
WURCS=1.0/1,0/[X212h|1,5]
X-7910
Xyl
Xylo-Pfan (TN)
Xylomed
Xylopyranose
Xylopyranose (6CI,7CI,8CI,9CI)
Xylopyranoside
Xylose
Xylose (USP)
Xylose, European Pharmacopoeia (EP) Reference Standard
Xylose, United States Pharmacopeia (USP) Reference Standard
Xyloside

US Patents and Regulatory Information for XYLO-PFAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Savage Labs XYLO-PFAN xylose POWDER;ORAL 017605-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Colorcon
Citi
Deloitte
Harvard Business School
Daiichi Sankyo
Cerilliant
Johnson and Johnson
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.